Found 11 matching trials
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) PHASE3 To Determine the Effects of Seladelpar on Normalization of Alkaline Phospha...
Show More Location
The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health
Learn More & Join Trial
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) PHASE3 An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Se...
Show More Status
Active Not Recruiting
Location
Arkansas Diagnostic Center
Learn More & Join Trial
Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC). PHASE2 A prospective, open-label, single-arm, investigator-initiated study (SELIC)...
Show More Location
Multiple Locations
Learn More & Join Trial
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis PHASE3 To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with ...
Show More Location
University of Alabama at Birmingham
Learn More & Join Trial
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC PHASE2 The objectives of this study are to evaluate the effect of seladelpar treat...
Show More Location
Sutter Pacific Medical Foundation - California Pacific Medical Center
Learn More & Join Trial
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) PHASE2 A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed...
Show More Location
CymaBay Research Site
Learn More & Join Trial
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) PHASE1 The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An ...
Show More Location
Arizona Liver Health
Learn More & Join Trial
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) PHASE2 An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-we...
Show More Location
Institute for Liver Health
Learn More & Join Trial
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) PHASE3 A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the sa...
Show More Location
Institute for Liver Health
Learn More & Join Trial
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) PHASE3 The purposes of this study are to evaluate the treatment effect of seladelp...
Show More Location
The Institute for Liver Health DBA Arizona Liver Health
Learn More & Join Trial